Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse

Gut

Volumn 56, Issue 1, 2007, Pages 121-128

  Georgiev, P ^a   Navarini, A A ^b   Eloranta, J J ^a   Lang, K S ^b   Kullak Ublick, G A ^a   Nocito, A ^a   Dahm, F ^a   Jochum, W ^a   Graf, R ^a   Clavien, P A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CHOLESTASIS; CONTROLLED STUDY; HEPATITIS; HISTOPATHOLOGY; HYPERBILIRUBINEMIA; LISTERIA MONOCYTOGENES; LIVER ISCHEMIA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN INDUCTION; REPERFUSION; RNA SYNTHESIS;

ANIMALS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CHOLESTASIS; DISEASE MODELS, ANIMAL; INFLAMMATION; ISCHEMIA; LISTERIA INFECTIONS; LIVER; MICE; MICE, INBRED C57BL; NEUTROPHILS; NF-KAPPA B; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 33845970269     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.097170     Document Type: Article

References (37)

1. Nishio H, Hidalgo E, Hamady ZZ, et al. Left hepatic trisectionectomy for hepatobiliary malignancy: results and an appraisal of its current role. Ann Surg 2005;242:267-75.
2. Dixon JM, Armstrong CP, Duffy SW, et al. Factors affecting morbidity and mortality after surgery for obstructive jaundice: a review or 373 patients. Gut 1983;24:845-52.
3. Tracy TF Jr, Bailey PV, Goerke ME, et al. Cholestasis without cirrhosis alters regulatory liver gene expression and inhibits hepatic regeneration. Surgery 1991;110:176-83.
4. Yoshidome H, Miyazaki M, Shimizu H, et al. Obstructive jaundice impairs hepatic sinusoidal endothelial cell function and renders liver susceptible to hepatic ischemia/reperfusion. J Hepatol 2000;33:59-67.
5. Zwacka RM, Zhou W, Zhang Y, et al. Redox gene therapy for ischemia/reperfusion injury of the liver reduces API and NF-kappaB activation. Nat Med 1998;4:698-704.
6. Rudiger HA, Clavien PA. Tumor necrosis factor alpha, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology 2002;122:202-10.
7. Selzner N, Rudiger H, Graf R, et al. Protective strategies against ischemic injury of the liver. Gastroenterology 2003;125:917-36.
8. Luedde T, Assmus U, Wuestefeld T, et al. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 2005;115:849-59.
9. Sewnath ME, Levels HH, Oude Elferink R, et al. Endotoxin-induced mortality in bile duct-ligated rats after administration of reconstituted high-density lipoprotein. Hepatology 2000;32:1289- 99.
10. Lechner AJ, Velasquez A, Knudsen KR, et al. Cholestatic liver injury increases circulating TNF-alpna and IL-6 and mortality after Escherichia coli endotoxemia. Am J Respir Crit Care Med 1998;157:1550-8.
11. Osawa Y, Hannun YA, Proia RL, et al. Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver. Hepatology 2005;42:1320-8.
12. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123:1238-51.
13. Abe T, Aral T, Ogawa A, et al. Kupffer cell-derived interleukin 10 is responsible for impaired bacterial clearance in bile duct-ligated mice. Hepatology 2004;40:414-23.
14. Rudiger HA, Graf R, Clavien PA. Sub-lethal oxidctive stress triggers the protective effects of ischemic preconditioning in the mouse liver. J Hepatol 2003;39:972-7.
15. Popowski K, Eloranta JJ, Saborowski M, et al. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol Pharmacol 2005;67:1629-38.
16. Schierwagen C, Bylund-Fellenius AC, Lundberg C. Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol Methods 1990;23:179-86.
17. Day Y-J, Marshall MA, Huang L, et al. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol 2004;286:G285-93.
18. Oreopoulos GD, Wu H, Szaszi K, et al. Hypertonic preconditioning prevents hepatocellular injury following ischemia/reperfusion in mice: a role for interleukin 10. Hepatology 2004;40:211-20.
19. Baranano DE, Rao M, Ferris CD, et al. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002;99:16093-8.
20. Kato Y, Shimazu M, Kondo M, et al. Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase-1 preconditioning. Hepatology 2003;38:364-73.
21. Fan C, Li Q, Zhang Y, et al. IkappaBalpha and IkappaBbeta possess injury context-specific functions that uniquely influence hepatic NF-kappaB induction and inflammation. J Clin Invest 2004;113:746- 55.
22. Suetsugu H, Iimuro Y, Uehara T, et al. Nuclear factor {kappa}B inactivation in the rat liver ameliorates short term total warm ischaemia/reperfusion injury. Gut 2005;54:835-42.
23. Miyoshi H, Rust C, Guicciardi ME, et al. NF-kappaB is activated in cholestasis and functions to reduce liver injury. Am J Pathol 2001;158:967-75.
24. Colletti IM, Remick DG, Burtch GD, et al. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990;85:1936-43.
25. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-66.
26. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 1990;10:1498-506.
27. Pamer EG. Immune responses to Listeria monocytogenes. Nat Rev Immunol 2004;4:812-23.
28. Cousens LP, Wing EJ. Innate defenses in the liver during Listeria infection. Immunol Rev 2000;174:150-9.
29. Lavon I, Goldberg I, Amit S, et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med 2000;6:573-7.
30. Kayal S, Lilienbaum A, Join-Lambert O, et al. Listeriolysin O secreted by Listeria monocytogenes induces NF-kappaB signalling by activating the IkappaB kinase complex. Mol Microbiol 2002;44:1407-19.
31. Soares MP, Seldon MP, Gregoire IP, et al. Heme oxygenase-1 modulates the expression of adhesion molecules associated with enaothelial cell activation. J Immunol 2004;172:3553-63.
32. Hansen TW, Cashore WJ. Rates of bilirubin clearance from rat brain regions. Biol Neonate 1995;68:135-40.
33. Hajrasouliha AR, Tavakoli S, Jabehdar-Maralani P, et al. Cholestatic liver disease modulates susceptibility to ischemischaemia/ reperfusion-induced arrhythmia, but not necrosis and hemodynamic instability: the role of endogenous opioid peptides. J Hepatol 2005;43:491-8.
34. Tjanara K, Woodman RC, Swain MG. Impaired neutrophil microbicidal activity in rat cholestasis. Gastroenterology 1997;112:1692-8.
35. Dussurget O, Cabanes D, Dehoux P, et al. Listeria monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal and hepatic phases of listeriosis. Mol Microbiol 2002;45:1095-106.
36. Briones V, Blanco MM, Marco A, et al. Biliary excretion as possible origin of Listeria monocytogenes in fecal carriers. Am J Vet Res 1992;53:191-3.
37. Hardy J, Francis KP, DeBoer M, et al. Extracellular replication of Listeria monocytogenes in the murine gall bladder. Science 2004;303:851-3.